<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654329</url>
  </required_header>
  <id_info>
    <org_study_id>3641</org_study_id>
    <secondary_id>Agreement # 10698</secondary_id>
    <nct_id>NCT00654329</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine vs Fentanyl for BMT</brief_title>
  <acronym>DexBMT</acronym>
  <official_title>Dexmedetomidine for Peri-operative Sedation and Analgesia in Children Undergoing Bilateral Myringotomy With Tube Placement (BMT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled clinical trial to examine effects of intranasal dexmedetomidine, an
      Î±2-adrenorecptor agonist, on pain control and agitation in children undergoing BMT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Pain</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Pain greater than a zero reported in the Post Anesthesia Care Unit (PACU)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Stay in PACU</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Total time from PACU entry until discharge</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Otitis</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine 1microgram/kilogram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 1microgram/kilogram intranasal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 2 micrograms/kilogram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 2 micrograms/kilogram intranasal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl 2 micrograms/kilogram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fentanyl 2 micrograms/kilogram intranasal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline placebo intranasal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Normal saline, given intranasally</description>
    <arm_group_label>Normal saline placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Fentanyl, nasal transmucosal, 2 micrograms/kilogram</description>
    <arm_group_label>Fentanyl 2 micrograms/kilogram</arm_group_label>
    <other_name>Actiq, Fentora</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine, transmucosal, 1 microgram/kilogram</description>
    <arm_group_label>Dexmedetomidine 1microgram/kilogram</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine, 2 microgram/kilogram, transmucosal route</description>
    <arm_group_label>Dexmedetomidine 2 micrograms/kilogram</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must meet all of the following inclusion criteria to be eligible for
             participation:

               1. The subject is 6 months to 6 years of age

               2. The subject's American Society of Anesthesiologists (ASA) physical status is ASA
                  1 or 2 (see appendix 1)

               3. The subject is scheduled for elective bilateral myringotomy with tube placement

               4. The subject's parent/legally authorized guardian has given written informed
                  consent to participate

                  Exclusion Criteria:

          -  Subjects will be excluded from study participation if any of the following exclusion
             criteria exists:

               1. The subject has a history or a family (parent or sibling) history of malignant
                  hyperthermia

               2. The subject has known significant renal or hepatic disorders determined by
                  medical history, physical examination or laboratory tests

               3. The subject has a known or suspected allergy to opioid analgesics or
                  dexmedetomidine

               4. The subject has history of. cardiovascular issues which would preclude the use of
                  dexmedetomidine, (e.g. Down's Syndrome, dysrhythmias, conditions where
                  hypotension is to be avoided)

               5. The subject has know central nervous system disease or neurological impairment

               6. The subject is an ASA classification of 3 or greater (See Appendix 1)

               7. The subject has a medical condition requiring an intravenous induction (i.e.
                  severe uncontrolled gastro-esophageal reflux)

               8. The subject refuses inhalation induction

               9. The subject is scheduled for a surgical sub-procedure (i.e. adenoidectomy,
                  tonsillectomy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia C Finkel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2008</study_first_posted>
  <results_first_submitted>February 23, 2011</results_first_submitted>
  <results_first_submitted_qc>March 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2011</results_first_posted>
  <last_update_submitted>March 28, 2011</last_update_submitted>
  <last_update_submitted_qc>March 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Julia C. Finkel, MD</name_title>
    <organization>Children's National Medical Center</organization>
  </responsible_party>
  <keyword>Dexmedetomidine, transmucosal, myringotomy,</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine 1microgram/Kilogram</title>
          <description>Dexmedetomidine 1microgram/kilogram (mcg/kg) intranasal</description>
        </group>
        <group group_id="P2">
          <title>Dexmedetomidine 2 Micrograms/Kilogram</title>
          <description>Dexmedetomidine 2 micrograms/kilogram (mcg/kg) intranasal</description>
        </group>
        <group group_id="P3">
          <title>Fentanyl 2 Micrograms/Kilogram</title>
          <description>Fentanyl 2 micrograms/kilogram (mcg/kg) intranasal</description>
        </group>
        <group group_id="P4">
          <title>Normal Saline Placebo</title>
          <description>Normal saline placebo intranasal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine 1microgram/Kilogram</title>
          <description>Dexmedetomidine 1microgram/kilogram (mcg/kg) intranasal</description>
        </group>
        <group group_id="B2">
          <title>Dexmedetomidine 2 Micrograms/Kilogram</title>
          <description>Dexmedetomidine 2 micrograms/kilogram (mcg/kg) intranasal</description>
        </group>
        <group group_id="B3">
          <title>Fentanyl 2 Micrograms/Kilogram</title>
          <description>Fentanyl 2 micrograms/kilogram (mcg/kg) intranasal</description>
        </group>
        <group group_id="B4">
          <title>Normal Saline Placebo</title>
          <description>Normal saline placebo intranasal</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.92" spread=".94"/>
                    <measurement group_id="B2" value="2.17" spread="1.51"/>
                    <measurement group_id="B3" value="2.25" spread="1.47"/>
                    <measurement group_id="B4" value="2.17" spread="1.66"/>
                    <measurement group_id="B5" value="2.14" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Pain</title>
        <description>Pain greater than a zero reported in the Post Anesthesia Care Unit (PACU)</description>
        <time_frame>up to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 1microgram/Kilogram</title>
            <description>Dexmedetomidine 1microgram/kilogram (mcg/kg) intranasal</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 2 Micrograms/Kilogram</title>
            <description>Dexmedetomidine 2 micrograms/kilogram (mcg/kg) intranasal</description>
          </group>
          <group group_id="O3">
            <title>Fentanyl 2 Micrograms/Kilogram</title>
            <description>Fentanyl 2 micrograms/kilogram (mcg/kg) intranasal</description>
          </group>
          <group group_id="O4">
            <title>Normal Saline Placebo</title>
            <description>Normal saline placebo intranasal</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Pain</title>
          <description>Pain greater than a zero reported in the Post Anesthesia Care Unit (PACU)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay in PACU</title>
        <description>Total time from PACU entry until discharge</description>
        <time_frame>up to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine 1microgram/Kilogram</title>
            <description>Dexmedetomidine 1microgram/kilogram (mcg/kg) intranasal</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 2 Micrograms/Kilogram</title>
            <description>Dexmedetomidine 2 micrograms/kilogram (mcg/kg) intranasal</description>
          </group>
          <group group_id="O3">
            <title>Fentanyl 2 Micrograms/Kilogram</title>
            <description>Fentanyl 2 micrograms/kilogram (mcg/kg) intranasal</description>
          </group>
          <group group_id="O4">
            <title>Normal Saline Placebo</title>
            <description>Normal saline placebo intranasal</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay in PACU</title>
          <description>Total time from PACU entry until discharge</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="26"/>
                    <measurement group_id="O2" value="88" spread="69"/>
                    <measurement group_id="O3" value="46" spread="25"/>
                    <measurement group_id="O4" value="48" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine 1microgram/Kilogram</title>
          <description>Dexmedetomidine 1microgram/kilogram (mcg/kg) intranasal</description>
        </group>
        <group group_id="E2">
          <title>Dexmedetomidine 2 Micrograms/Kilogram</title>
          <description>Dexmedetomidine 2 micrograms/kilogram (mcg/kg) intranasal</description>
        </group>
        <group group_id="E3">
          <title>Fentanyl 2 Micrograms/Kilogram</title>
          <description>Fentanyl 2 micrograms/kilogram (mcg/kg) intranasal</description>
        </group>
        <group group_id="E4">
          <title>Normal Saline Placebo</title>
          <description>Normal saline placebo intranasal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Heart rate dropped to 42 bpm for 2 min post-op.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julia C. Finkel, MD</name_or_title>
      <organization>Children's National Medical Center</organization>
      <phone>202-476-4867 ext 4867</phone>
      <email>jfinkel@cnmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

